BioMarin
BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor
BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity
BioMarin Acquires Inozyme Pharma for $270M, Gaining Phase 3 Rare Disease Therapy
BioMarin; Inozyme Pharma; acquisition; rare disease; INZ-701; ENPP1 Deficiency; enzyme replacement therapy; Phase 3 clinical trial
BioMarin’s R&D Chief Warns of Innovation Slowdown Amid NIH Funding Cuts
BioMarin, NIH funding, biomedical innovation, genetic diseases, drug development, research partnerships
Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges
Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.
BioMarin and CAMP4 Collaborate on RNA-Targeting Therapies for Rare Genetic Diseases
BioMarin, CAMP4, RNA-targeting therapies, genetic diseases, regulatory RNA, RAP Platform, antisense oligonucleotides, ASOs, rare genetic conditions
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
BioMarin Undergoes Strategic Restructuring Amid Slow Roctavian Sales and Staff Layoffs
BioMarin, restructuring, Roctavian, staff layoffs, corporate strategy, hemophilia gene therapy
BioMarin Announces Significant Workforce Reduction Amid Restructuring Efforts
BioMarin, layoffs, restructuring, biotech, rare diseases, gene therapy, Roctavian, hemophilia A
BioMarin Appoints Industry Veterans from Amgen and Roche in Executive Revamp
BioMarin, executive restructuring, Amgen, Roche, Greg Friberg, James Sabry, Roctavian, hemophilia A gene therapy
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs